Exploring the evolution of upstream & downstream viral vector processing 

Cell & Gene Therapy Insights 2023; 9(3), 287–294

DOI: 10.18609/cgti.2023.045

Published: 2 April
Francesca Vitelli

David McCall, Commissioning Editor, Cell & Gene Therapy Insights speaks to Francesca Vitelli, VP, Cell Therapy and AAV Process Development, Intellia Therapeutics

Francesca Vitelli brings over 20 years’ experience to her current role leading viral vector and cell therapy process development, manufacturing sciences and vector core services at Intellia Therapeutics. She has held technical leadership roles in Process and Analytical Development, Manufacturing, and Tech Ops at a multinational CDMO and regenerative medicine start-ups and has worked with cell types including HSCs, iPSCs and T cells, viral vectors including AAV and LVV and many supporting production systems. Prior, she was an assistant professor of molecular development and disease after her PhD in medical genetics. Designing and deploying innovation to improve the lives of those impacted by genetic disease has motivated Francesca’s journey through academia, entrepreneurship and industry.